The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Authors:
- Sarah BlachSBSarah Blach
- Karolin FalconerKFKarolin Falconer
- Martin KåbergMKMartin Kåberg
- Homie RazaviHRHomie Razavi
- Soo AlemanSASoo Aleman
- 12 August 2014
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 50 (2) , 233-244
Abstract
OBJECTIVE. Recently, new highly effective direct-acting antivirals (DAAs) against hepatitis C virus (HCV) were introduced. Whether these will alleviate the anticipated increase of liver disease burden in Sweden is unknown, partly because high costs may restrict the use. The objectives were to model the HCV epidemic in Sweden, the burden of disease, and the potential impact of different treatment strategies. HCV disease progression was modeled to 2030. Scenarios were simulated using new DAAs with sustained annual treatment rate (n = 1130), reduced treatment rate (n = 380) to maintain budget, and increased treatment rates (n = 1430 or 2260) to reduce HCV infections. With today's triple therapies, the estimated number of serious liver complications and death are expected to peak in 2021. Using new DAAs among F0-F4 patients, an unchanged annual treatment rate can reduce the number of HCV infections by 10% by 2030; however, hepatocellular carcinoma (HCC) and mortality will remain unchanged. By reducing to 380 treatments annually and focusing on patients with advanced fibrosis (F3-F4), serious complications will remain constant but the total number of HCV infections will increase. By doubling the number of DAA treatments, HCC-incidence and liver-related deaths would decrease by 65-70% by 2030. Mortality and HCC can be reduced with new DAAs and sustained treatment uptake when restricted to F2-F4 patients, or with increased uptake in F0-F4 patients. Treatment restrictions to limit cost may reduce the positive effects and increase the burden of HCV infection. These results may be important for the future strategies of HCV management.Keywords
This publication has 44 references indexed in Scilit:
- Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV‐infected, evaluated patientsAlimentary Pharmacology & Therapeutics, 2013
- The burden of hepatitis C in Sweden: a national study of inpatient careJournal of Viral Hepatitis, 2011
- Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and genderScandinavian Journal of Infectious Diseases, 2009
- Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendationsScandinavian Journal of Infectious Diseases, 2009
- Lower‐than‐standard dose peg‐IFN alfa‐2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight‐based ribavirinJournal of Viral Hepatitis, 2008
- Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community‐based register studyJournal of Viral Hepatitis, 2008
- Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosisScandinavian Journal of Gastroenterology, 2008
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996
- HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profileInfection, 1995
- Risk Factor Exposure Among Hepatitis C Virus RNA Positive Swedish Blood Donors - The Role of Parenteral and Sexual TransmissionScandinavian Journal of Infectious Diseases, 1995